EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY-NC-ND 4.0

Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial

Ruth P Lim iD, Salma Qassin, Lucy McKenna, Emma Hornsey, Dominic Italiano, Leonid Churilov, Richard J MacIsaac, Jas-Mine Seah, Elif I Ekinci iD, Austin EMPA‐MRI Study Group

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70950 ↗

At a glance

Randomisierte kontrollierte Studie in Diabetes, Obesity and Metabolism, 2026. Written by Ruth P Lim and 9 co-authors. Institution: Austin Health, Heidelberg, Australia. Major MEDLINE topics: Glucosides, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Kidney. 58 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Boehringer Ingelheim, Royal Australian and New Zealand College of Radiologists.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aims

Empagliflozin is renoprotective in Type 2 diabetes mellitus (T2DM). Our primary aim was to assess empagliflozin's effect on glomerular filtration rate and renal vascular resistance using multiparametric MRI (MpMRI). Our secondary aim was to assess the impact of empagliflozin on additional MpMRI‐derived metrics including markers of tissue oxygenation and microstructure. Materials and Methods Prospective randomised open‐label crossover clinical trial of adults with T2DM with eGFR ≥ 45 mL/min/1.73 m 2 and any degree of albuminuria (CKD KDIGO G1, 2 or GF3a, A1–A3). MpMRI was performed at baseline and 12‐weeks post‐empagliflozin or active comparator sitagliptin therapy in random order with an interval washout period. Brochner‐Mortensen corrected MRI‐derived GFR (MRI‐GFR), renal vascular resistance (RVR), renal blood flow (RBF) and markers of tissue hypoxia (R2*) and microstructure were measured. Impact of empagliflozin or sitagliptin on MpMRI and laboratory metrics were assessed with mixed‐effect linear regression.

Results

Twelve participants (8 male, 4 female) completed all study visits. Following empagliflozin, there were significant mean decreases in MRI‐GFR (3.03 mL/min/1.73 m 2 ) and RBF (41.24 mL/min) and increased medullary hypoxia (R2* 1.81 s −1 ) compared to sitagliptin, all p < 0.05. There were no statistically significant changes to RVR, corticomedullary microstructure, eGFR or albuminuria observed with empagliflozin.

Conclusions

Multiparametric MRI can non‐invasively demonstrate local renal impacts of empagliflozin beyond that of traditional markers of renal function, including decreased GFR and medullary hypoxia. Lack of RVR change may relate to lower systemic blood pressure, concurrent medication and efferent arteriolar vasodilation in T2DM. Trial Registration: ACTRN12619000933156

Subjects

MeSH terms (MEDLINE)

GlucosidesBenzhydryl CompoundsDiabetes Mellitus, Type 2KidneySodium-Glucose Transporter 2 InhibitorsDiabetic NephropathiesHumansFemaleMalePilot ProjectsMagnetic Resonance ImagingMiddle AgedGlomerular Filtration RateCross-Over StudiesAgedProspective StudiesSitagliptin PhosphateVascular ResistanceRenal Circulation

Author keywords

SGLT2 inhibitordiabetic nephropathydrug mechanismempagliflozinpharmacodynamicstype 2 diabetes

Substances

GlucosidesempagliflozinBenzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsSitagliptin Phosphate

Authors and institutions

  • Austin Health, Heidelberg, Australia.
  • Melbourne Medical School, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Australia.
  • Australian Centre for Accelerating Diabetes Innovations, School of Medicine, University of Melbourne, Parkville, Australia.
  • Department of Medicine, St Vincent's Hospital Melbourne, University of Melbourne, Fitzroy, Australia.
  • Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Australia.

ORCID profiles: Ruth P Lim, Elif I Ekinci

Funding

  • Boehringer Ingelheim
  • Royal Australian and New Zealand College of Radiologists

Cite

APA

Lim, R. P., Qassin, S., McKenna, L., Hornsey, E., Italiano, D., Churilov, L., MacIsaac, R. J., Seah, J. M., Ekinci, E. I., & Austin EMPA‐MRI Study Group (2026). Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70950

Vancouver

Lim RP, Qassin S, McKenna L, Hornsey E, Italiano D, Churilov L, et al. Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70950

BibTeX
@article{Lim2026,
  author = {Lim, Ruth P and Qassin, Salma and McKenna, Lucy and Hornsey, Emma and Italiano, Dominic and Churilov, Leonid and MacIsaac, Richard J and Seah, Jas-Mine and Ekinci, Elif I and Austin EMPA‐MRI Study Group, Austin EMPA‐MRI Study Group},
  title = {Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70950}
}
Start for free →